Aytu Biopharma, Inc. · NASDAQ:AYTU
Aytu Biopharma — Aytu Bioscience — Merger or Acquisition (December 2020)
19 slides from Aytu Biopharma's merger presentation, Dec 10, 2020
Slide 1: Aytu BioScience to Acquire Neos Therapeutics, Inc.
Aytu BioScience (NASDAQ: AYTU) Aytu BioScience to Acquire Neos Therapeutics, Inc. December 10, 2020 a ytubio.com 1
Slide 2: Transaction Highlights & Strategic Rationale
Transaction Highlights & Strategic Rationale x Transaction creates highly diversified specialty pharmaceutical company with $100mm of pro forma revenue ‒ Brand Marketing (10 products), Pediatric, Primary Care, and Consumer Healthcare products x Accelerates transformation to profitability with estima
Slide 3: Combination Overview
Combination Overview 3 Terms • Stock - for - Stock Transaction • Each holder of Neos shares will receive 0.1088x shares of common stock of Aytu per each share of Neos common stock held, reflecting a 1:10 reverse stock split effected 12/9/20 (1) • The all - stock transaction is valued, on a fully dil
Slide 4: Highly Diversified Specialty Pharmaceuticals Platform with $100 Million in Revenue
Highly Diversified Specialty Pharmaceuticals Platform with $100 Million in Revenue 4 (1) As of September 30, 2020. Pediatrics Primary Care Consumer Health Three Complementary Product Sets with Critical Mass in Pediatrics
Slide 5: Synergies will Create Robust Value and Expected to Drive Profitability
Synergies will Create Robust Value and Expected to Drive Profitability 5 Continued Opportunities for Synergies SG&A • Commercial efficiencies • Duplicative overhead • Support functions and technology systems Operations • Manufacturing optimization • Streamlined R&D Upwards of $15 Million Quick, effi
Slide 6: NEOS's ADHD Portfolio: A Market Expansion Opportunity
NEOS’s ADHD Portfolio: A Market Expansion Opportunity 6 Approved for patients 6+ years, both pediatric and adult • Focused on adults – the fastest growing segment of the market Approved for patients ages 6 - 17 • Compelling clinical efficacy data demonstrating symptom control at 1 hour after dosing
Slide 7: Large and Growing ADHD Market
Large and Growing ADHD Market Product Background 7 Drug Type Annual Prescriptions 1 (Million) Annual Gross Revenue 2 (Billion) Amphetamine 48.5 $5.6 Methylphenidate 19.6 $2.6 Non - Stimulants 6.9 $0.3 Total 75.1 $8.5 • Adzenys XR - ODT launched in 2016 • Cotempla XR - ODT launched in 2017 • Adzenys
Slide 8: Neos RxConnect Program Will Support and Grow Aytu's Heritage Brands
Neos RxConnect Program Will Support and Grow Aytu’s Heritage Brands 8 • Offers predictability and enhances access to Neos brands for 100% of commercially insured patients, regardless of individual insurance coverage - Allows prescribers to focus on best therapeutic option, rather than on individual
Slide 9: New Product Opportunity Creates Future Growth
New Product Opportunity Creates Future Growth 9 NT0502 is in Phase 1 clinical development for the treatment of chronic sialorrhea (excessive drooling) • Significant unmet need for an effective therapy with an improved tolerability profile and dosing regimen Source: Mozaffarian. AHA Circulation. 2016
Slide 10: Combined Companies Create Platform to Drive Growth and Support Acquisitions
Combined Companies Create Platform to Drive Growth and Support Acquisitions 10 Unique opportunity to acquire assets as a consolidator in a market ripe for integration Existing Portfolio Expected to Grow and Generate Cash Flow Ability to Accelerate Growth Through Smart Acquisitions Potential to Unloc
Slide 11: Experienced Executive Leadership
Experienced Executive Leadership Josh Disbrow Chairman and CEO, Aytu BioScience • Former VP of Commercial Operations at Arbor Pharmaceuticals; revenues grew from zero to over $127MM in < 5 years; Acquired by KKR • Previous COO of Ampio Pharmaceuticals (NYSE: AMPE) and head of Business Unit • Progres
Slide 12: Transaction Next Steps
Transaction Next Steps 12 x Announce Close Announce the deal and file merger agreement. Subject to customary review and closing requirements. Obtain shareholder approvals. Expected to close in the second quarter of 2021. Shares to be traded under Aytu Bioscience (AYTU) on the Nasdaq. Review
Slide 13: Supplemental Information
SUPPLEMENTAL INFORMATION 13
Slide 14: Overview of Aytu BioScience
Overview of Aytu BioScience • Focus: Licenses/acquires and commercializes novel prescription and consumer health products competing in large markets • Rx Products: Natesto, Tuzistra XR, ZolpiMist • Consumer Health Products : Over 20 consumer brands • Finances: – $13.520m net product revenue (Q1 2021
Slide 15: Overview of Neos Therapeutics
Overview of Neos Therapeutics • Focus: Develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform • Products: Adzenys XR - ODT amphetamine, Cotempla XR - ODT methylphenidate; Adzenys ER amphetam
Slide 16: NT0502 Development Program Phase 1 Single and Multiple Ascending Dose Study
NT0502 Development Program Phase 1 - Single and Multiple Ascending Dose Study 16 Study Element Details Study Design • Single center, two part, randomized, double blind, placebo - controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study Dose • SAD: 3 cohorts, single dose of NT0
Slide 17: Additional Information about the Proposed Merger Transaction and Where to Find It
Additional Information about the Proposed Merger Transaction and Where to Find It This communication relates to the proposed merger transaction pursuant to the terms of the Agreement and Plan of Merger, dated as of December 9, 2020, by and among Neos Therapeutics, Inc. (“Neos”), Aytu Bioscience Inc.
Slide 18: No Offer or Solicitation; Forward-Looking Statements
No Offer or Solicitation This communication does not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor a solici tat ion of any vote or approval with respect to the proposed merger transaction or otherwise. No offering of securities shall be made except by means
Slide 19: Contact Information
19 Contact Information: Josh Disbrow Chief Executive Officer josh.disbrow@aytubio.com Investor Relations: James Carbonara Hayden IR james@haydenir.com Transfer Agent: Direct Transfer info@issuerdirect.com 877 - 481 - 4014
Aytu Bioscience — Merger or Acquisition (December 2020) on 6ix